Healthtech & Wellness VC Funds

Andera Partners, established in 2001 and headquartered in Paris, is a prominent private equity firm specializing in investments in life sciences, growth capital, and buyouts. The firm has built a strong reputation for its expertise in supporting companies at various development stages, particularly within the biotech and medical technology sectors. One of Andera's flagship initiatives is the BioDiscovery fund family, which has collectively raised over €1.1 billion to date. Their latest fund, BioDiscovery 6, closed at €456 million, highlighting significant investor confidence. This fund targets innovative therapeutic products and medical technologies, investing in companies across Europe and the United States. Notable investments include companies like Evommune, Amolyt, and TargED. Andera Partners employs a hands-on approach, providing both financial and strategic support to its portfolio companies. The firm's life sciences team, comprising experienced professionals like Sofia Ioannidou, Olivier Litzka, and Gilles Nobécourt, plays a crucial role in guiding startups from the preclinical stages to commercialization. Their strategic partnerships and extensive network bolster their ability to support high-potential innovations.

Andreessen Horowitz (a16z), headquartered in Menlo Park, California, is a premier venture capital firm known for its significant impact on the tech industry. Founded in 2009 by Marc Andreessen and Ben Horowitz, the firm has invested in high-profile startups such as Facebook, Airbnb, GitHub, and Coinbase. Their portfolio boasts a diverse range of industries, including AI, biotech, fintech, and consumer tech. A16z has a unique approach to investing, combining capital with extensive support. Their investments range from seed to late-stage funding, with recent high-profile investments including Mistral AI and Pinecone. They actively support their portfolio companies through a robust ecosystem of resources, including a market development team, operating partners, and a talent network​​. The firm is also heavily involved in emerging technologies, particularly in the cryptocurrency and blockchain space. They have launched dedicated funds for crypto investments and established initiatives like the a16z Crypto School to educate and support founders in this domain. Furthermore, their Cultural Leadership Fund aims to enhance diversity and inclusion in the tech industry​​. For founders, a16z's focus on innovation and long-term support makes them an attractive partner. They value visionary, dedicated founders and look for startups with significant market potential and disruptive capabilities. This holistic support strategy sets a16z apart, offering more than just financial investment but also strategic guidance and network access to help startups thrive.

Angel Invest is a Berlin-based super angel fund and one of the most active early-stage investors in Europe, founded in 2017. Deploying approximately €125K per deal, the fund invests in roughly 100 startups per year across software, fintech, AI, e-commerce, healthtech, and clean technology. With 230 portfolio companies that have collectively raised over €2 billion in follow-on funding and carry a combined market capitalization exceeding €4 billion, Angel Invest has established a record of high-volume, high-conviction investing at the pre-seed and seed stages. Beyond capital, the fund provides each portfolio company with at least one year of active coaching. It has also built the Angel Invest Perks Platform, offering up to €4 million in curated credits, discounts, and partner access to support early operations. In 2025, the firm co-founded the Technology Briefing Center (TBC) in Berlin alongside Signal Iduna, an initiative analyzing AI, fintech, and climate tech trends to bridge innovation and strategic decision-making. Angel Invest's model deliberately prioritizes breadth and speed at the earliest stage — writing small checks quickly across a wide range of sectors and geographies within Europe. The fund's coaching commitment distinguishes it from passive micro-VCs: founders receive structured support during their first year, when operational guidance carries the most leverage. The combination of volume, mentorship infrastructure, and a growing perks platform creates compounding value across the portfolio.

Angel Ventures is the first professionally managed angel investor network in Latin America, founded in August 2008 in Mexico City. One of the region's most active and influential venture firms, Angel Ventures leads Series Seed and Series A rounds in startups building innovative business models for the Latin American market. Fund I closed at $20 million in 2012, backing 21 companies; Fund II targeted $120 million to expand across the Pacific Alliance countries — Chile, Colombia, Mexico, and Peru. The Inter-American Development Bank (IDB) is among the fund's limited partners. With 110 total investments and a network of 300 co-investing angel members, Angel Ventures covers a broad range of sectors: fintech, e-commerce, healthtech, agribusiness, food technology, AI, and media. The team of 23 includes seven partners, one venture partner, and nine principals operating across Mexico and the United States. Typical check sizes range from $100K to $3 million, with the firm leading rounds at both seed and Series A stages. As a pioneer of the LatAm venture ecosystem, Angel Ventures has spent nearly two decades building the infrastructure that modern Latin American venture capital relies on — angel co-investment networks, institutional fund structures, and the cross-border relationships that connect Mexican and regional founders to global capital. The firm's combination of institutional discipline and deep regional knowledge makes it one of the formative forces in Latin American technology investing.

AngelBay is an angel investment network based in Gurugram, India, founded in 2020 by Piush Goyal, Shweta Agarwal, and Sorabh Agarwal. The firm focuses on early-stage startups, primarily investing at the seed and Series A stages. AngelBay's investments span a range of industries, including fintech, retail, healthcare, and enterprise applications. Their portfolio includes around 27 companies, with recent investments in startups like FinQY and Amocare. AngelBay not only offers capital but also provides strategic guidance to help startups scale. They are known for co-investing alongside other prominent networks like Venture Catalysts and Faad Network, highlighting their collaborative approach to venture funding. With a strong focus on the Indian startup ecosystem, AngelBay has also participated in deals in international markets such as France. The network is highly active, having made 78 investments to date, with notable exits like TABLT Pharmacy and InstaOffice. AngelBay's mission is to support founders in transforming existing markets and building sustainable businesses through hands-on involvement and strategic partnerships.

Angelini Ventures is the corporate venture capital arm of Angelini Industries, founded in 2021 and headquartered in Rome, Italy. With a capital commitment of €300 million, Angelini Ventures focuses on early-stage investments in biotechnology, digital health, and life sciences. The firm aims to leverage technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations. The firm has made significant investments globally, including in Europe, North America, and Israel, with a particular emphasis on brain health and consumer segments such as women, children, and the elderly. Notable portfolio companies include Pretzel Therapeutics, Argobio, Serenis, and Nouscom. Angelini Ventures is led by CEO Paolo Di Giorgio, who has extensive experience in the pharmaceutical and investment sectors. The team includes experts such as Elia Stupka, Managing Director, and Gabriela Manrique, Partner, among others, spread across major innovation hubs globally​.

Angels Santé, established in 2008 and based in Paris, is the largest healthcare-focused business angel network in Europe. It supports early-stage startups in the Biotech, Medtech, and Digital Health sectors, helping bring innovative solutions to market that benefit patients. With over 100 investments made since its inception, the organization fosters partnerships between entrepreneurs and healthcare professionals, providing not only capital but also deep industry expertise in clinical, regulatory, and scientific domains. Each year, Angels Santé finances 10-15 deals, with a focus on Europe, but its reach extends globally through partnerships with organizations like EBAN and Business Angels Europe. This international collaboration allows Angels Santé to facilitate cross-border investments and provide startups with access to a broader market. The network emphasizes a hands-on approach, guiding startups through the complexities of the healthcare landscape by offering mentorship and connections to relevant stakeholders. Notable figures such as Eric Garnier, the president, emphasize the critical role that healthcare innovation plays in solving modern challenges. Furthermore, their US branch, based in Boston, extends opportunities for French-speaking investors in the United States to support healthcare startups with global aspirations. Angels Santé is not just about funding; it's about building a community dedicated to advancing healthcare through innovation, with a long-term commitment to improving patient outcomes and supporting the growth of impactful healthcare companies.

AngelsDeck is a global venture capital network that operates through a unique club model, connecting investors and startups for syndicated investment deals. Founded with the mission to create an international ecosystem for venture deal syndication, AngelsDeck has established itself as a key player in supporting early-stage startups across a variety of industries. With over 14 chapters worldwide and 500 active members, AngelsDeck provides a platform for investors to co-invest in high-growth startups from regions including the US, Europe, the Middle East, and Asia. The firm focuses primarily on seed to pre-Series B companies, with a keen interest in sectors such as technology, healthcare, and sustainability. By leveraging its network of investors, AngelsDeck facilitates joint investments that allow startups to scale quickly while benefiting from strategic mentorship and financial backing. AngelsDeck also runs a startup bootcamp, providing early-stage companies with access to investors and resources to accelerate their growth. One of the unique aspects of AngelsDeck is its ability to create an exclusive and collaborative investment community, where deals are syndicated across its global chapters. This enables investors to pool resources and expertise, speeding up the funding process for startups. AngelsDeck’s investment model emphasizes long-term growth and market expansion, with a clear focus on supporting innovative startups with the potential to disrupt industries.

Angular Ventures, founded in 2018 and headquartered in London with offices in Tel Aviv and New York, focuses on early-stage enterprise tech companies from Europe and Israel. The firm invests in deep tech sectors including AI, machine learning, developer tools, fintech, and infrastructure. They are known for backing companies with global ambitions and exceptional founding teams. Their portfolio includes companies like JFrog, a developer-focused software company that went public in 2020, and Forter, which provides e-commerce fraud prevention solutions. Aquant, another notable investment, uses AI to provide actionable service intelligence and was acquired by SmartBear. Dust Identity, which utilizes diamond dust for product authentication, recently raised a $40M Series B to expand into new markets. Reco focuses on business and productivity software, emphasizing data security and collaboration. Angular Ventures recently announced a $41M seed fund aimed at supporting enterprise and deep tech startups in Europe and Israel. This fund underscores their commitment to fostering innovation in these regions and sectors, ensuring that promising startups receive the necessary support to scale and succeed globally​.

ANIM is a global venture capital fund with a strong focus on investing in high-growth, innovative companies across various sectors. Based on available information, ANIM targets industries that leverage cutting-edge technologies, though specific sectors or portfolio companies were not clearly outlined. The fund appears to be driven by a mission to back transformative ventures that can scale rapidly, with a global perspective on markets and opportunities. ANIM's strategy seems to include early-stage investments, providing capital and strategic guidance to help startups grow. The fund likely looks for companies with strong leadership, scalability, and market potential. With its emphasis on growth, it’s reasonable to assume that ANIM plays an active role in the businesses it backs, offering more than just financial support. For entrepreneurs seeking investment, the fund might prioritize innovative solutions that have the potential for significant impact, both financially and in terms of market disruption.

Animal Capital, founded in 2020 and based in New York, is a venture capital firm that focuses on investments in consumer technology, financial technology, health and wellness, and media sectors. This firm is distinguished by its unique approach, leveraging the influence of its founders, who are prominent social media stars such as Josh Richards, Griffin Johnson, and Noah Beck, to drive consumer awareness and engagement for its portfolio companies. Notable investments by Animal Capital include Breakr, a platform connecting artists with influencers; Step, a banking app aimed at helping teenagers build credit and learn financial literacy; and Super Coffee, a sugar-free, enhanced coffee brand. Other significant investments include Colossal Laboratories & Biosciences, which focuses on biotechnology, and Zurp, a social platform software company. Animal Capital's strategy involves providing traditional venture capital services such as fundraising and scaling companies, alongside leveraging the founders' broad networks and influence to impact consumer purchasing decisions. This Gen Z-focused approach aims to set new standards in the investment space by effectively tapping into the purchasing power and cultural influence of younger generations.

Animo Ventures is a venture capital firm dedicated to backing early-stage founders who are passionate and willing to go all in. Based in Miami with additional offices in New York and San Francisco, Animo focuses on pre-seed and seed investments in the U.S., cutting checks that range from $500,000 to $2.5 million. The firm actively invests in sectors like fintech, enterprise software, digital health, B2B, and consumer-facing technology, aiming to nurture high-growth startups from ideation to early traction​. What sets Animo apart is its radically founder-focused approach. The firm operates without layers of analysts or associates, meaning founders work directly with general partners throughout the investment process. The team, led by Nico Berardi and Antonio Osio, is deeply involved in all aspects of the startups they back, offering not only capital but also strategic guidance. Animo reserves a significant portion of its fund for follow-on investments, ensuring long-term support​. Animo’s portfolio includes notable companies such as Nearpod, Intello, Morty, and Ironclad, with a particular focus on fintech and enterprise SaaS. The firm is not only a financial backer but also acts as a strategic partner, leveraging a dense network of connections to help with fundraising, hiring, and scaling. With its "people backing people" ethos, Animo builds genuine, long-term relationships with founders, committed to seeing them succeed through every challenge and milestone​.

Ankur Capital is an early-stage venture capital firm based in India, specializing in transformative technologies targeting the next billion people. Founded with a mission to support innovative business models addressing core challenges in sectors such as agriculture, healthcare, education, and fintech, Ankur Capital invests in both digital technology and deep science technology-led companies. Their portfolio includes companies like Cropin, which is driving smart farming; Niramai, pioneering early breast cancer detection with AI; and StringBio, which converts greenhouse gases into value-added proteins. Ankur Capital is dedicated to creating impact through responsible agriculture, climate mitigation and adaptation, and inclusive growth. The firm emphasizes hands-on support, working closely with entrepreneurs from seed to scale. Through their in-house platform, AnkurGro, they provide strategic guidance and operational assistance to help founders navigate their growth journey.

Anorak Ventures, founded in 2016 and headquartered in San Francisco, is a seed-stage venture firm that focuses on investing in transformative technology and people. The firm primarily invests in pre-seed and seed-stage companies across various technology sectors, including artificial intelligence and machine learning (AI/ML), Internet of Things (IoT), robotics, and consumer tech. Anorak Ventures has invested in over 120 seed-stage technology companies, which now represent an aggregate market capitalization of $24.8 billion. Notable investments in their portfolio include companies such as Vantage Point, WeatherCheck, Orderful, Framework, Prisms VR, Better Health, and Marxent. They are dedicated to helping these companies achieve product-market fit and secure follow-on financing. The firm, led by Managing Partner Greg Castle, aims to support innovative startups by providing not just capital but also strategic guidance to help them scale and succeed in competitive markets​.

ANRI is a venture capital firm based in Tokyo, Japan, focusing primarily on seed and early-stage investments. Founded with the mission to drive innovation, ANRI has invested in over 260 companies, emphasizing sectors such as electric vehicles, recycling, manufacturing, and information technology. Notable investments by ANRI include startups like Turing, a manufacturer in the electric vehicle sector, and amu, which focuses on recycling and waste management. Their portfolio showcases a strong commitment to diverse industries, including health tech and fintech. ANRI's investment approach often involves co-investing with other significant players in the market, thereby enhancing their portfolio companies' growth and market reach. ANRI has successfully achieved exits with companies like Raksul, DELY, and Coincheck, highlighting their capability to nurture startups towards profitable outcomes. Their investment philosophy emphasizes supporting innovative ideas that have the potential to make substantial impacts globally. The firm is also committed to diversity and inclusion, having set and achieved goals to increase investments in startups led by women. This dedication to fostering a diverse entrepreneurial ecosystem is part of ANRI's broader strategy to drive meaningful change and innovation in the startup landscape​.

Anterra Capital is a venture capital firm that specializes in investments within the food and agricultural technology sectors. Founded in 2013, Anterra Capital has offices in Amsterdam and Boston and focuses on backing innovative companies that address critical challenges in agriculture, food production, and sustainability. Their portfolio includes notable investments such as Enko Chem, which develops novel crop protection products; ProducePay, a financial and data services platform for the fresh produce industry; and BiomEdit, which focuses on microbiome innovation for animal health. The firm manages over $450 million in assets and typically invests in Series A or B rounds, with initial checks ranging from $1 to $10 million. Anterra is committed to leveraging biotechnology and digital solutions to transform the food system, improve consumer health, and enhance the livelihoods of farmers. Their investment strategy emphasizes impact and sustainability, aligning with their goal to create a resilient and sustainable food system. Anterra Capital has raised significant funds, including a $260 million second Global Food and Agriculture Technology Fund, which continues to support biotech and digital innovations in the agrifood sector​.

Anthem Venture Partners, founded in 2000 and based in Santa Monica, California, is a venture capital firm specializing in early-stage Series A and B investments. The firm primarily focuses on technology companies in Southern California, investing in sectors like software, internet, semiconductors, and new media​. Anthem typically invests between $1 million to $5 million in its portfolio companies and often takes a board seat, indicating a hands-on approach. The firm aims to be the first institutional investor, leading or co-leading the investments. Notable investments by Anthem Venture Partners include Surf Air, indie Semiconductor, Scopely, and Bird Global. The firm has a track record of successful exits, such as the IPO of Surf Air Mobility and the acquisition of Scopely by Savvy Games Group for $4.9 billion​. The team is led by founder and Managing General Partner William Woodward, along with partners like Claudia Llanos and Entrepreneur-in-Residence Sudhin Shahani. The firm's philosophy emphasizes building strong relationships with founders and taking a personal stake in the success of each investment​.

Anthemis Group, founded in 2010 and headquartered in London, is a global investment platform dedicated to fostering innovation in the financial system. The firm focuses on fintech, insurtech, and related sectors, investing from seed to growth stages. Anthemis' portfolio includes notable companies such as Betterment, eToro, and Currencycloud. They also back innovative startups like Pipe, Weavr, and Atomic. With over 150 investments worldwide, Anthemis emphasizes diversity and inclusivity, with 23% of their portfolio companies founded by women and 40% led by women or BIPOC. Their commitment to diversity is further demonstrated through the Female Innovators Lab, which supports female founders in fintech across the UK and Europe. Anthemis recently closed multiple funds totaling over $700 million, expanding their support for fintech companies throughout their lifecycle. The firm also launched an ESG-focused SPAC to advance sustainable finance. Anthemis' thesis-driven approach leverages deep market insights to drive systemic, long-term change. Led by founder Amy Nauiokas and CEO Briana van Strijp, Anthemis is poised to continue its mission of reinventing finance through innovation, collaboration, and inclusivity, supporting the next wave of fintech innovation globally.

Anthos Capital, founded in 2007 and based in Santa Monica, California, focuses on growth-stage investments in consumer products, technology, healthcare, and financial services sectors. The firm has made notable investments in companies like Carbon Robotics, known for its Autonomous Weeder which helps reduce reliance on herbicides, and Todyl, a comprehensive cybersecurity platform aimed at small and mid-market businesses. Anthos Capital takes a strategic partnership approach, providing not just capital but also operational and strategic support to help portfolio companies grow and lead their industries. They focus on investments that promise significant growth and impact, supporting companies from early to growth stages with tailored assistance. The firm's recent investment activities include significant funding rounds for companies like Carbon Robotics and Todyl, reflecting their commitment to fostering innovation and industry leadership. Their portfolio showcases a diverse range of companies, emphasizing Anthos Capital's ability to identify and nurture high-potential ventures across various sectors.

Antler is a globally renowned early-stage venture capital firm known as the "day zero investor," backing founders from the inception of their startups. With over 850 investments in 20+ countries, Antler has notable portfolio companies like Airalo, a global eSIM provider, and has recently raised a $60 million MENAP fund to further support startups in the Middle East, North Africa, and Pakistan region. Antler focuses on sectors including technology, fintech, and digital innovation, providing personalized coaching, co-founder matching, and follow-on funding. Key team members include Dr. Jonathan Doerr and Romain Assunção, leading regional activities from Riyadh and Duba

ANU Connect Ventures is a Canberra, Australia-based venture capital firm founded in 2005 with a mandate to commercialize research from The Australian National University, the University of Canberra, and Charles Sturt University. The firm supports university research with commercial potential in proof-of-concept work, then invests in the most promising opportunities emerging from ACT-based academic institutions and local R&D companies. Two funds are under management: the Discovery Translation Fund and a $37 million Seed Investment fund structured as the ANU-MTAA Super Venture Capital Partnership. A team of seven — including two partners and three principals — has built a portfolio of nine companies primarily in life sciences and enterprise technology over more than twelve years of active investing. The firm leads rounds at pre-seed and seed stages, deploying $500K to $3 million per investment. Sectors include biotech, deep tech, software, and health technology, reflecting the research strengths of its university partners. ANU Connect Ventures occupies a critical position in Australia's innovation pipeline: bridging the gap between academic discovery and commercial application in a region where startup infrastructure has historically been limited. By anchoring its mandate to world-class research institutions, the firm sources differentiated deal flow that is difficult to access through conventional venture channels. Its patient, commercialization-focused approach serves founders who are translating scientific breakthroughs into viable businesses for the first time.

Anyon is a Germany-based venture capital firm focused on investing in early-stage technology companies that are digitizing the real estate industry. Established in 2016, Anyon operates with offices in Berlin, Frankfurt, and Munich. The firm primarily targets PropTech and IoT startups that aim to modernize real estate operations and management. Leveraging their expertise in real estate, Anyon partners with entrepreneurs to help them scale by offering strategic support, operational insights, and access to their network of industry experts. Anyon typically invests in pre-seed and seed-stage startups with ticket sizes ranging from €100k to €1.5 million. Their portfolio includes companies like Thing-it, an IoT platform for managing smart buildings, and Alasco, a construction management software designed to streamline financial processes in real estate projects. Anyon’s investment approach is deeply integrated with their platform, allowing startups to benefit from shared resources and technology infrastructure, driving value creation in their portfolio. The firm is led by founding partners Rupprecht Rittweger and Dr. Dennis Lips, who combine decades of experience in real estate and technology to guide the companies they back toward long-term growth and success.

Aonia Ventures is a Paris-based micro-VC firm founded in 2020 with roots in Switzerland, investing in 20 to 30 technology startups per year worldwide at seed and Series A stages. The firm deploys €100K to €250K per deal across healthtech, fintech, greentech, foodtech, wellness, and lifestyle — sectors where Aonia sees urgent problems and scalable solutions converging. A team of three partners runs the fund, maintaining a high-volume, hands-on investment cadence across Europe and the United States. With 55 portfolio companies and counting, Aonia has accumulated a track record that includes one unicorn — Alan, the French health insurance platform — and one public market exit via Field Trip Health and Wellness. These outcomes anchor the portfolio's credibility against a backdrop of broad, consistent early-stage deployment across multiple sectors and geographies. Aonia's model is deliberately high-frequency: by writing smaller checks across a large number of bets each year, the firm maximizes exposure to breakout outcomes while building a portfolio network with compounding cross-sector value. The fund's particular strength in health and wellness, combined with greentech and fintech coverage, reflects founders' growing interest in businesses that address large systemic challenges — a thesis Aonia has pursued since its founding and continues to refine with each cohort of investments.

APA Venture Partners is a San Francisco-based pre-seed and seed-stage venture capital firm founded in 2020, focused on founders who are automating legacy industries. The firm targets healthcare, B2B SaaS, and consumer technology — sectors where outdated processes create substantial displacement opportunity for technology-led challengers. APA was founded by individuals with significant institutional VC and company-building experience, combining that background with high-touch operational support and curated access to Fortune 500 companies. The firm leads rounds and typically writes checks of $100K to $1 million, with 16 investments to date across its target sectors. Portfolio companies include DataPlor, a location intelligence data company, alongside other early-stage businesses in logistics and consumer mobility. APA invests exclusively in the United States, maintaining a national scope while operating from its San Francisco base. APA Venture Partners calls its target founders 'rule-breakers' — operators who have identified inefficiencies in established industries and possess the domain expertise to replace incumbent processes with better technology. The firm's value proposition extends well beyond capital: the team provides hands-on operational guidance and broker introductions to major corporate partners, giving portfolio companies a meaningful commercial runway advantage in the earliest, most fragile stage of company building.

Apax Partners is a leading global private equity advisory firm with a focus on inspiring growth and transforming businesses. Founded nearly 50 years ago, Apax has raised and advised over 30 funds, managing more than $77 billion in aggregate capital. The firm primarily invests in four sectors: Tech, Services, Healthcare, and Internet/Consumer. Apax operates several strategic funds, including Apax Global Buyout, which focuses on transformative growth in key sectors, and Apax Digital Growth, aimed at accelerating tech companies. Additionally, Apax Global Impact targets companies that deliver tangible societal and environmental benefits, while Apax Mid-Market Israel leverages local expertise to support growth in Israeli businesses. The firm also has Apax Credit and Apax Listed Private Equity strategies to provide a flexible investment approach across the capital structure​. Notable investments include Auto Trader Group, GlobalLogic, and Cole Haan, among others. Apax leverages its deep sector expertise and global network to drive operational excellence and digital transformation within its portfolio companies. The firm’s extensive experience and strategic focus have made it a prominent player in private equity globally, with offices in major financial hubs including London, New York, Hong Kong, and Tel Aviv​.

Aperture Venture Capital (Aperture VC) is a venture capital firm founded in 2021, based in Radnor, Pennsylvania. The firm focuses on investing in early-stage companies, particularly those led by diverse founders who are building the future of fintech and enterprise software. Aperture VC's mission is to redefine the venture capital landscape by supporting the "Multicultural Mainstream," which includes Black, Latinx, and female entrepreneurs. Aperture VC’s unique approach involves its Diversity Investing API℠, a platform designed to connect corporate partners with diverse talent and market innovations. This platform also provides portfolio companies with critical operating resources to help them scale. The firm believes that by investing in diverse founders, they can unlock untapped potential and drive significant impact in the venture capital ecosystem. Aperture VC has quickly gained recognition in the industry, attracting investments from major corporations like PayPal, which have recognized the value of supporting diverse founders. The firm is committed to fostering an inclusive ecosystem where diverse entrepreneurs can thrive and achieve successful exits.

APEX Ventures is a venture capital firm based in Vienna, Austria, specializing in deep tech and medical technology startups. Founded in 2016, APEX Ventures invests in early-stage companies across Europe, with a focus on innovations in AI, quantum computing, automation, robotics, computer vision, space technology, and medical technology. The firm emphasizes backing startups with unique, defensible technologies that have the potential to disrupt and transform their respective industries​. In 2023, APEX Ventures partnered with Amadeus Capital Partners to launch the Amadeus APEX Technology Fund, which aims to raise €80 million to support deep tech startups primarily in the DACH region (Germany, Austria, and Switzerland). This fund focuses on seed and Series A investments, typically ranging from €1 million to €1.5 million. The partnership combines APEX’s local expertise and network with Amadeus’ extensive global experience in venture capital. APEX Ventures has a diverse portfolio, including companies like contextflow, ImageBiopsy Lab, and Mobius Labs. The firm is known for providing not just capital but also strategic support, leveraging their deep tech expertise and strong networks to help startups scale and succeed​.

Apollo Global Management, a leading global alternative investment manager, has a diverse and extensive portfolio across various sectors. As of 2024, Apollo manages approximately $548 billion in assets, with substantial investments in private equity, credit, and real estate. In the private equity space, Apollo's portfolio includes companies like ADT Inc., a major provider of security and automation solutions; CareerBuilder, an online employment service; and The Fresh Market, a specialty grocery retailer. They also have significant holdings in the healthcare sector with companies like LifePoint Health and R1 RCM Inc. Apollo is known for its strategic acquisitions across multiple industries. Notable recent acquisitions include U.S. Silica, a producer and supplier of silica sand, and Modern Aviation, a premium aviation services provider. Additionally, Apollo has made significant investments in the travel and hospitality sector, exemplified by its acquisition of Great Wolf Resorts and Diamond Resorts International. The firm's investment strategy focuses on creating value through buyouts, corporate carve-outs, and distressed asset investments. This approach has enabled Apollo to build a robust portfolio that spans various geographies, primarily the United States and the United Kingdom, with a strong presence in the energy and financial services sectors.

Apollo Health Ventures is a transatlantic venture capital firm founded in 2016 and headquartered in Berlin, Germany. Co-founded and led by Managing Director Nils Regge, the firm's singular mission is to fund and co-build companies that target the root causes of aging and age-related diseases. Apollo focuses on breakthrough science in Alzheimer's disease, heart disease, cancer, sarcopenia, and frailty — with the ultimate goal of extending healthy human lifespan. The firm takes an active company-building role, frequently co-founding portfolio companies alongside scientists and entrepreneurs. Apollo leads rounds and has made approximately 13 investments across Seed and Series A stages, with seed rounds averaging $9.7 million and Series A rounds averaging $34 million. Notable portfolio companies include Auron Therapeutics, HAYA Therapeutics, Cleara Biotech, Cognito Therapeutics, and Aeovian Pharmaceuticals. The portfolio spans the United States and Europe, reflecting the firm's transatlantic orientation and its Bio Fund I structure. Apollo Health Ventures differentiates itself through its company-building model: the team does not passively invest in existing longevity companies but actively participates in their creation, recruiting scientists, shaping research strategy, and guiding early clinical positioning. This founder-in-residence approach concentrates portfolio expertise in a narrow therapeutic category and allows Apollo to shape the science from the earliest stages — well before most investors enter the conversation.

Apple Tree Partners (ATP) is a distinguished venture capital firm focused on life sciences, founded in 1999 by Dr. Seth Harrison. With offices in New York, San Francisco, and Cambridge, ATP has committed $2.9 billion in capital, making it one of the key players in biotech venture investing. The firm’s approach is unique in that it both creates and invests in companies, often starting from early-stage scientific ideas or asset spinouts from other companies. ATP provides flexible capital and strategic support to foster the development of science-driven enterprises. The firm is involved in every stage of a company’s life cycle, from seed investments to IPO and beyond. Notably, ATP has been instrumental in launching over 30 life sciences companies, of which 19 have gone public or been acquired. Some successful portfolio companies include Chinook Therapeutics, Akero Therapeutics, and Stoke Therapeutics​. In addition to financial backing, ATP brings operational expertise to its portfolio companies, helping them navigate clinical trials, regulatory processes, and market entry strategies. The firm has pioneered advancements in fields such as oncology, metabolic diseases, and inflammatory disorders, combining deep scientific understanding with entrepreneurial rigor. ATP’s investments, including its recent creation of Deep Apple Therapeutics, exemplify its commitment to using cutting-edge technologies like AI and machine learning to accelerate drug discovery and deliver life-changing therapies.

Applied Ventures is the venture capital arm of Applied Materials, based in Santa Clara, California. Since its establishment in 2006, the firm has focused on early-stage investments, primarily within deep technology sectors such as semiconductors, energy, advanced materials, and life sciences. Applied Ventures has a global reach, with investments spanning across North America, Europe, Asia-Pacific, and the Middle East. The firm is known for its flexibility, investing up to $100 million annually and actively participating in funding rounds ranging from $10 to $50 million. Its strategy emphasizes supporting startups with disruptive technologies by connecting them to Applied Materials' global ecosystem, which includes industry partners, supply chain resources, and technical expertise. Key portfolio companies include Ayar Labs (optical I/O technology), Rockley Photonics, and TXOne Networks, reflecting its focus on innovations that align with Applied Materials' core strengths in materials engineering and semiconductor technology​. The investment team is led by Anand Kamannavar, who serves as Global Head, alongside key figures such as Brad McManus, John Wei, and Rajesh Ramanujam, all based in Santa Clara. Applied Ventures is stage-agnostic, supporting both early and growth-stage startups as they scale globally, especially those involved in deep tech advancements.

Apposite Capital is a London-based venture capital firm specializing in the healthcare sector. Founded in 2006, the firm focuses on investing in innovative healthcare companies across the UK and Europe. Apposite Capital provides a mix of venture, development, and growth financing, along with buyout capital, primarily targeting companies that can significantly impact healthcare through improved services and technologies. Their investment strategy emphasizes supporting companies with scalable business models and strong growth potential. Apposite Capital has a track record of successful investments in healthcare services, medical devices, diagnostics, and digital health. The firm typically takes an active role in its portfolio companies, providing strategic guidance and leveraging its extensive network within the healthcare industry to drive growth and innovation. Apposite Capital's team brings a combination of operational, scientific, and financial expertise, allowing them to deeply understand and support the unique needs of healthcare businesses. They also focus on promoting best practices in environmental, social, and governance (ESG) and are committed to making a positive impact through their investments. Recent notable investments include companies like NIMGenetics, HCML, and Emblation, showcasing their commitment to advancing healthcare solutions and improving patient outcomes​.

APX is a Berlin-based venture capital firm that focuses on pre-seed investments, supporting startups at the earliest stages. Founded in 2018 as a joint venture between Axel Springer and Porsche, APX is known for backing digital business models and exceptional founding teams across Europe. It has invested in over 185 companies, spanning industries such as fintech, SaaS, consumer services, and mobility. APX is committed to being a long-term partner, often serving as the first investor for many startups. They typically provide initial funding up to €500,000, with follow-on support available as companies grow. In 2023, they launched HEARTFELT, a new fund focused on continuing early-stage investments while managing their existing portfolio. With a hands-on approach, APX offers not just capital but also guidance on sales, operations, and strategic partnerships. Their network of experienced investors and successful entrepreneurs plays a key role in helping startups scale.

Aqua-Spark, based in the Netherlands, is a global investment fund dedicated to sustainable aquaculture. Founded in 2013 by Mike Velings and Amy Novogratz, the fund aims to transform the aquaculture industry by promoting environmental and social sustainability alongside financial returns. Aqua-Spark's mission is to make the production of aquatic life such as fish, shellfish, and plants safe, accessible, and environmentally friendly. The fund manages around $450 million in assets and has invested in 24 companies across the aquaculture value chain, aiming to expand its portfolio to 50-60 companies. Some notable investments include eFishery, an Indonesian aquaculture tech startup, Calysta, a biotech company producing sustainable feed ingredients, and Wanda Fish, which is developing cultivated bluefin tuna. Aqua-Spark focuses on early-stage investments, typically at the Series A stage, and supports companies through to maturity. Their investments are chosen for their potential to generate significant environmental and social impacts while delivering solid financial returns. The fund has a diverse investor base of around 300 investors from over 25 countries.

Aquarius Equity is a UK-based venture capital firm with a strong focus on early-stage investments in high-growth companies, particularly those located in the North of England. The firm, established to bridge the venture capital gap in this region, is dedicated to supporting innovative startups that have the potential to scale significantly. Their latest fund, the Aquarius Origin Fund, targets investments of up to £750,000, focusing on sectors like biotechnology, life sciences, and technology. Aquarius Equity's investment strategy emphasizes scalability and sustainability, with a particular interest in companies that align with the UN Sustainable Development Goals. They seek out companies with proven business models and significant growth potential, especially those that have already secured investment from industry-recognized investors. The firm also encourages investments from private individuals through Self Invested Personal Pension (SIPP) schemes, allowing them to invest in early-stage companies traditionally dominated by institutional funds. Aquarius Equity is not just a financial backer but also an active partner, providing strategic support to help startups achieve their growth ambitions. The firm’s commitment to innovation and sustainability positions it as a key player in the venture capital landscape, particularly in the UK’s underserved Northern regions.

marArali Ventures, founded in 2017 and based in Bangalore, India, is a venture capital firm focused on early-stage investments in enterprise tech startups. The firm primarily targets companies in India but has also invested in the United States and Singapore. Their investment strategy includes sectors such as artificial intelligence, fintech, healthtech, and high tech. Notable investments by Arali Ventures include Wingman, a conversational AI for sales, and Insent, a B2B enterprise sales platform acquired by ZoomInfo in 2021. Other significant investments include Protecto in business services and Wiz Freight in logistics tech​. Arali Ventures has made 28 investments to date and has achieved notable exits with companies like Insent and Wingman. The firm is currently raising its second seed fund, aiming for $30-40 million, to continue supporting startups in SME tech, industrial automation, and robotics​. Their team, led by Managing Partner Rajiv Raghunandan, provides extensive support to portfolio companies, emphasizing a hands-on approach and deep industry expertise. This supportive environment has made them a highly founder-friendly VC firm.

Aravis is a private equity firm based in Zurich, Switzerland, founded in 2001 by Jean-Philippe Tripet. The firm focuses on high-tech growth investments, primarily in the biotech, creative and digital, and industrial high-tech sectors. Aravis has sponsored multiple fund vintages and has deployed over USD 400 million across four funds. Aravis Growth I LP, their latest initiative, targets investments in established, innovative Swiss and European companies with significant growth potential. This fund aims to fill the gap in growth capital in the region by offering strategic advice, access to networks, and capital to accelerate companies through their growth phases​. The team at Aravis is composed of experienced professionals from various backgrounds, including finance, industry, and technology, providing a wealth of knowledge and expertise to support their portfolio companies. Their investment approach also integrates ESG criteria, aligning with several UN Sustainable Development Goals (SDGs).

ARAX Capital Partners, founded in 2007 and based in Vienna, Austria, is a venture capital firm that focuses on early-stage investments across the life sciences and technology sectors. They are particularly invested in Austrian ventures, targeting young, innovative companies, especially those with patentable technology. ARAX is committed to fostering the growth of startups in these fields by providing significant strategic and financial support. The firm's notable investments include Calyxha Biotechnologies, EveliQure Biotechnologies, and Panoptes Pharma, showcasing their emphasis on biotech and life sciences. Additionally, they have invested in technology companies like The MoonVision and crystalsol, a renewable energy company​​. ARAX Capital Partners generally participates in funding rounds ranging from $1 million to $9 million and has made 41 investments to date. They typically lead rounds, indicating their active role in shaping the growth trajectories of their portfolio companies​​. The team at ARAX is led by experienced partners such as Christian Tiringer, Beatrix Schuberth, and Thomas Cimbal, who bring extensive expertise in venture capital and entrepreneurship to the firm​​. This leadership helps ARAX maintain a strong network and high-quality deal flow, positioning them as a key player in Austria’s venture capital landscape. For startups, ARAX Capital Partners is a valuable partner, particularly for those in the early stages of development, looking for both capital and strategic guidance to scale their innovative solutions in the biotech and technology sectors​.

Arboretum Ventures, headquartered in Ann Arbor, Michigan, is a prominent venture capital firm specializing in the healthcare sector. Founded in 2002 by Jan Garfinkle and Tim Petersen, the firm manages $1 billion across six funds. Arboretum Ventures focuses on capital-efficient investment opportunities in medical devices, life science tools, diagnostics, tech-enabled care delivery, and pharma adjacencies​. The firm has a strong commitment to investing in under-ventured geographies, particularly in the Midwest. Their portfolio includes a variety of innovative companies such as NeuMoDx, which was acquired by QIAGEN, and Fifth Eye, known for its early warning system for patient care​. Arboretum's investment strategy emphasizes supporting startups that aim to reduce healthcare costs while improving patient outcomes. They are active partners, providing strategic guidance and leveraging their extensive network to help portfolio companies succeed. The team includes managing partners Jan Garfinkle, Dr. Tom Shehab, Dan Kidle, and other key members like Paul McCreadie and Marcy Marshall. Overall, Arboretum Ventures stands out for its proactive involvement with entrepreneurs and its focus on transformative healthcare solutions that address significant industry challenges​,

Arc Ventures is a New York-based venture capital firm that connects founders with a global network of funds, advisors, and industry experts. Focused on fostering innovation, Arc Ventures operates as the venture arm of a single family office, originally part of Arc Group Holdings. The firm emphasizes long-term partnerships and operates across diverse geographies, including the U.S., Israel, and Europe, with plans to expand into Asia. Founded in 2019, Arc Ventures invests in both startups and venture funds, supporting entrepreneurs in sectors like fintech, health tech, digital media, and autonomous driving. Notable companies in their portfolio include Arbe Robotics, Alpha Tau, and Allure Security. The firm leverages its extensive network to introduce founders to potential customers, funding sources, and strategic partners, helping them scale quickly. The firm prides itself on a unique approach that blends data-driven insights with human connections, ensuring that promising ventures receive both financial backing and the mentorship needed to thrive.

Arch Venture Partners is a powerhouse in venture capital, specializing in early-stage investments in life sciences and technology. With a notable portfolio that includes industry leaders like Grail, Illumina, and Denali Therapeutics, Arch focuses on groundbreaking innovations that transform healthcare and biotech. They have a strong geographic footprint in the United States, with significant investments also in China and the UK. Their investment strategy centers on nurturing disruptive technologies with high-impact potential. Arch Venture Partners typically leads investment rounds, deploying substantial capital to accelerate growth, evidenced by their recent $2.975 billion Fund XII. The firm prioritizes deep scientific expertise and collaborates closely with founders to guide long-term strategic development. Average check sizes vary, but their robust funding capabilities mean they often make sizable commitments. Founded in 1986, Arch is driven by a team of seasoned professionals, including co-founder Robert Nelsen, who has been instrumental in the success of numerous billion-dollar companies. The firm values direct and collaborative approaches from startups, emphasizing the importance of innovative ideas backed by solid research. Overall, Arch Venture Partners stands out for its dedication to pioneering science and technology, its active role in funding and strategy, and its impressive track record of high-profile successes.

Archangel Ventures is a Melbourne-based pre-seed and seed venture capital firm founded in 2020 by Ben Armstrong, Rayn Ong, and Quentin Wallace. The firm specializes in SaaS and information technology companies across Australia, New Zealand, and Southeast Asia, writing initial checks of $20K to $500K at the earliest formation stages. Ben Armstrong, Managing Partner and 2025 Investor of the Year at the Governor of Victoria Startup Awards, brings 15 years of VC experience from Telstra Ventures and a prolific angel track record. Rayn Ong is recognized for 100-plus early-stage bets across the Australian technology ecosystem. Archangel has made 73 investments across SaaS, software, healthtech, and fintech, with two portfolio exits. Notable portfolio companies include Heidi, a medical AI company that raised a $65 million Series B, Atelier, a supply chain-as-a-service platform for health and beauty, and Pearler, an all-in-one personal finance application. The firm leads rounds and maintains active engagement with founders throughout the earliest years of company building. Archangel was built by operators for founders: the partners' collective 175-plus pre-seed deals reflect a philosophy of backing people before products, particularly in the Australian and Southeast Asian markets where early-stage capital has historically been thin. The firm's hands-on model is designed for the pre-seed stage specifically — when capital alone is insufficient and experienced operator judgment is the scarcest resource a founder can access.

Archetype is an early-stage venture capital firm that focuses on accelerating the decentralized future, primarily backing startups in the Web3 and cryptocurrency space. Founded in 2021 and based in New York, Archetype is led by founder Ash Egan and a team of experienced professionals from the crypto, investing, and engineering worlds. The firm invests in seed-stage companies, with check sizes typically ranging from $1M to $3M. They also lead many of their funding rounds. Archetype is known for backing founders who are disrupting traditional industries by creating entirely new markets within the decentralized economy. The firm's portfolio includes standout names like Alchemy, Socket, and Mona, all of which focus on cutting-edge technologies in crypto infrastructure, blockchain development, and decentralized applications. Archetype’s investment philosophy is centered on supporting founders with deep technical expertise and a vision for decentralization. They are highly active in the U.S., with a particular focus on startups that bring innovation to financial services, infrastructure, and software development. The firm also provides strategic guidance, leveraging its team’s extensive network within the crypto ecosystem to help startups grow from concept to market-ready products. By combining their expertise in both technology and operations, Archetype positions itself as a critical partner for crypto founders looking to build and scale innovative projects in the decentralized world.

Archimed Group, founded in 2014 and headquartered in Lyon, France, is a leading private equity firm specializing in the healthcare sector. The firm manages around €8 billion in assets and is focused on investing in small to midsize companies across seven key healthcare sectors, including Biopharma, MedTech, and Healthcare IT. Archimed’s strategy involves acquiring majority stakes in companies and working closely with them to accelerate growth, drive innovation, and expand internationally. Archimed has a strong track record, with its funds consistently ranking in the top decile for performance. The firm’s latest fund, MED Platform II, closed at €3.5 billion in 2023, making it the largest healthcare-only private equity fund raised by a European-based firm. This fund is primarily focused on mid-cap companies in Europe and North America, aiming to support healthcare leaders in scaling their operations through strategic acquisitions and capacity expansions. Archimed’s commitment to impact investing is evident through its alignment with sustainable development goals and its EURÊKA Foundation, which supports healthcare-related charitable initiatives. The firm’s unique blend of financial, medical, and operational expertise positions it as a key player in the global healthcare investment landscape.

Arcus Ventures is a New York-based venture capital firm founded in 2007 by Steven L. Soignet and James B. Dougherty, dedicated exclusively to oncology-focused life sciences companies. The team brings deep experience across clinical and academic medicine, drug development, hospital management, healthcare consulting, and private equity — a multi-disciplinary foundation that informs both investment selection and portfolio support. The firm closed a cancer-focused fund at $45 million in August 2014. Arcus leads rounds and targets three opportunity types: innovative biopharmaceuticals or drug delivery platforms in development, medical device companies approaching pre-marketing approval, and commercial-stage service businesses with positive revenue. Check sizes of $1 million to $5 million are deployed at Series A and Series B stages across North America and Europe. Notable portfolio companies include Cleave Therapeutics, Exosome Diagnostics, XTuit Pharmaceuticals, TRACON Pharmaceuticals, T2 Biosystems, and Vascular Pathways, collectively spanning drug discovery, diagnostics, biopharmaceuticals, and medical devices. Arcus Ventures' singular sector focus is its defining characteristic: by investing only in oncology, the firm develops a depth of scientific and commercial judgment that generalist healthcare funds cannot replicate. Soignet and Dougherty's combined clinical and entrepreneurial backgrounds allow them to evaluate not only the science but the regulatory and commercial pathway — providing portfolio companies with guidance that is specific, experienced, and directly applicable to the challenges of bringing cancer therapies to market.

Aleph VC, founded in 2013 and based in Tel Aviv, specializes in early-stage investments, primarily partnering with Israeli entrepreneurs. With $850 million under management, Aleph focuses on building meaningful companies and impactful global brands across various sectors, including fintech, digital health, cybersecurity, AI, and machine learning. Notable investments by Aleph include Lemonade, a full-stack global insurance company, and Melio, which provides digital payment tools for small businesses. Other prominent portfolio companies include Nexar, a dashcam and edge-AI platform for better driving, and Freightos, a digital freight marketplace. The firm has also seen significant exits, such as the acquisition of Raftt and the public offering of Freightos​. Aleph typically invests between $2 million and $12 million in seed and pre-seed stages, focusing on innovative companies poised for global expansion. The team, led by co-founders Michael Eisenberg and Eden Shochat, leverages their extensive network and expertise to provide strategic guidance and access to global markets, aiming to create long-term value for their portfolio companies.

Arena Ventures is a seed-stage venture capital firm based in Los Angeles and San Francisco, founded in 2015 by Jeff Lo and Paige Craig. The firm backs technology startups led by entrepreneurs who are uniquely positioned to transform their industry — with particular focus on what the team calls atypical founding teams: people whose unconventional backgrounds give them asymmetric insight into the problems they are solving. Arena is also notable as the first venture firm built from the ground up to collaborate with equity crowdfunding, helping AngelList backers become more effective investors. With 45 investments and eight portfolio exits — most recently Betterview in December 2023 — Arena Ventures has backed Clover Health, which went public via SPAC, and Andela, the talent marketplace that became a unicorn. Atrium LTS represents the firm's legal technology exposure. The fund writes checks of $100K to $1 million at Seed and Series A stages and invests exclusively in North America across software, fintech, healthtech, food and beverage, education, and real estate. Arena Ventures takes a disciplined approach to founder selection: the team invests heavily in understanding each founder's personal background and psychological makeup before committing capital. This founder-first philosophy translates into a small annual deal count — two to six investments per year — and sustained support well past the initial check, with the team described as willing to fight hard alongside founders through difficult stretches.

Argon Ventures, based in Cambridge, Massachusetts, is a pre-seed venture fund focusing on Intelligent Industry Solutions. Founded by Robert Mason and Andrew Feinberg in 2020, Argon Ventures targets early-stage investments in Big Data & Analytics, SaaS, and Software sectors. The firm leverages its deep operational expertise to support founders in building impactful global businesses. Notable investments include companies like EnFi, Cyvl.ai, and PeakMetrics, reflecting Argon's commitment to high-tech, data-driven solutions. Argon Ventures typically leads rounds with an average investment size of around $2M, showing a preference for hands-on engagement from the earliest stages. The firm has built a strong co-investor network, collaborating with prominent investors such as Techstars and Glasswing Ventures. Argon Ventures is characterized by its proactive support in areas like team building, product strategy, and market entry. The team, including seasoned professionals like Bob Mason, brings a combination of technical insight and business acumen, helping startups navigate their growth journeys effectively. With a robust portfolio and a strategic focus on innovative tech solutions, Argon Ventures positions itself as a key player in the venture capital landscape, fostering the next generation of transformative companies.

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.

Arkin Bio Ventures is a Tel Aviv-based life sciences venture capital firm founded in 2016 as part of Arkin Capital, a diversified global investment manager with over $2 billion in assets under management across twelve funds. Arkin Bio operates as a joint venture between Phoenix Group (49%) and Arkin Holdings (51%), and has raised three funds: Fund I in 2016, Fund II at $140 million in 2020, and Fund III at $100 million closed in January 2026 — bringing total life sciences AUM above $600 million. Managing Partner Dr. Pini Orbach and Partner Alon Lazarus lead a team of ten, including four partners. The firm leads rounds and invests $3 million to $20 million per company at early and mid-stage in biotech companies developing therapies in immunotherapy, cancer, metabolism, microbiome, autoimmune diseases, and drug delivery. With 27-plus investments and more than 20 successful exits through IPOs and acquisitions, Arkin Bio has backed UroGen Pharma, Keros Therapeutics, Bluejay Therapeutics, cCAM Biotherapeutics, Hi-Bio, and ImmPACT Bio, among others. Arkin Bio's partnership with Phoenix Group provides co-investment capacity that extends individual deal capability and supports portfolio companies through multiple rounds. The team works closely with founders on biological strategy, translational planning, and clinical positioning — going well beyond check-writing to serve as active scientific and commercial advisors during the most capital-intensive stages of drug development.